Resistance emerges to second-generation antiandrogens in prostate cancer

William G. Nelson; Srinivasan Yegnasubramanian

doi:10.1158/2159-8290.CD-13-0405

Resistance emerges to second-generation antiandrogens in prostate cancer

William G. Nelson, Srinivasan Yegnasubramanian

School of Medicine

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

The appearance of a mutant androgen receptor, ARF876L, in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs.

Original language	English (US)
Pages (from-to)	971-974
Number of pages	4
Journal	Cancer discovery
Volume	3
Issue number	9
DOIs	https://doi.org/10.1158/2159-8290.CD-13-0405
State	Published - Sep 2013

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-13-0405

Cite this

@article{c3ee04f59dbe470db19204ba83c6803b,

title = "Resistance emerges to second-generation antiandrogens in prostate cancer",

abstract = "The appearance of a mutant androgen receptor, ARF876L, in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs.",

author = "Nelson, {William G.} and Srinivasan Yegnasubramanian",

year = "2013",

month = sep,

doi = "10.1158/2159-8290.CD-13-0405",

language = "English (US)",

volume = "3",

pages = "971--974",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "9",

}

TY - JOUR

T1 - Resistance emerges to second-generation antiandrogens in prostate cancer

AU - Nelson, William G.

AU - Yegnasubramanian, Srinivasan

PY - 2013/9

Y1 - 2013/9

N2 - The appearance of a mutant androgen receptor, ARF876L, in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs.

AB - The appearance of a mutant androgen receptor, ARF876L, in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs.

UR - http://www.scopus.com/inward/record.url?scp=84885198106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885198106&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-13-0405

DO - 10.1158/2159-8290.CD-13-0405

M3 - Article

C2 - 24019330

AN - SCOPUS:84885198106

SN - 2159-8274

VL - 3

SP - 971

EP - 974

JO - Cancer discovery

JF - Cancer discovery

IS - 9

ER -

Resistance emerges to second-generation antiandrogens in prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this